Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond
Telemedicine in Oncology and Reimbursement Policy During COVID-19 and Beyond
复制标题
DOI：
10.6004/jnccn.2020.7639
复制
发表时间：
2021-12-01
影响因子：
13.4
通讯作者：
Benson, Al B., III
中科院分区：
文献类型：
--
作者：
Kircher, Sheetal M.;Mulcahy, Mary;Benson, Al B., III
美国于2020年1月20日报告了首例2019冠状病毒病（COVID-19）确诊病例。截至2020年9月17日，累计确诊病例超过660万例，死亡196,277例。关于免疫功能低下患者结局的数据有限，但中国早期发表的报告表明，癌症患者入住ICU、机械通气或死亡的风险是非癌症患者的3.5倍。由于COVID-19的不确定性，实践中必须限制对脆弱患者的暴露。在COVID-19疫情期间，远程医疗一直是护理癌症患者的基石之一。本综述概述了COVID-19大流行之前和期间公共和私人支付方的报销政策，描述了对癌症护理的影响，并为未来的报销政策提供了考虑因素。
The first confirmed case of coronavirus disease 2019 (COVID-19) in the United States was reported on January 20, 2020. As of September 17, 2020, there were more than 6.6 million confirmed cases and 196,277 deaths. Limited data are available on outcomes of immunocompromised patients, but early published reports from China indicate that those with cancer have a 3.5 times higher risk of ICU admission, mechanical ventilation, or death than those without cancer. Because of the uncertain behavior of COVID-19, it has become imperative for practices to limit exposure to vulnerable patients. Telemedicine has been one of the cornerstones of caring for patients with cancer during the COVID-19 pandemic. This review provides an overview of reimbursement policy by public and private payers before and during the COVID-19 pandemic, describes implications in cancer care, and offers considerations for future reimbursement policy.